

Year in Review: Clinical Investigators Provide Perspectives on the Most Relevant New Publications, Data Sets and Advances in Acute Myeloid Leukemia and Myelodysplastic Syndromes (Faculty Presentations)

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. The Phase III VIALE-C trial evaluating low-dose cytarabine (LDAC) in combination with either venetoclax or placebo for patients with newly diagnosed acute myeloid leukemia (AML) who were ineligible for standard induction therapy demonstrated which overall survival (OS) outcome?**
 - a. No statistically significant difference between the treatment arms
 - b. A statistically significant improvement with LDAC/venetoclax**
 - c. A statistically significant improvement with placebo/venetoclax
- 2. Enasidenib is FDA approved for patients with relapsed or refractory AML with which mutation?**
 - a. FLT3
 - b. IDH1
 - c. IDH2**
 - c. Bcl-2
- 3. Which of the following observations was presented at ASH 2020 by Dohner and colleagues regarding patients who received maintenance CC-486 (oral azacitidine) on the QUAZAR AML-001 trial but were identified as having early disease relapse (5% to 15% blasts in peripheral blood or bone marrow) and could then receive an escalated 21-day dosing cycle at investigators' discretion?**
 - a. The escalated 21-day CC-486 dosing regimen restored remission and was associated with better OS**
 - b. The escalated 21-day CC-486 dosing regimen did not restore remission or improve OS
- 4. Which of the following drug types best describes the mechanism of action of magrolimab?**
 - a. Hypomethylating agent
 - b. Bcl-2 inhibitor
 - c. Anti-CD47 monoclonal antibody**
- 5. On which treatment arm did the higher proportion of patients attain transfusion independence for ≥ 8 weeks in the Phase III study evaluating luspatercept versus placebo for patients with very low-, low- or intermediate-risk myelodysplastic syndromes with ring sideroblasts who had been receiving regular red blood cell transfusions?**
 - a. Luspatercept**
 - b. Placebo
 - c. Neither a nor b; the proportion was similar on both arms